EGEN, Inc., is a clinical stage biopharmaceutical company focused on developing nucleic acid-based therapeutics for cancer and other difficult to treat diseases using proprietary nanoparticle delivery systems. The Company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking.
EGEN-001 utilizing EGEN's proprietary TheraPlas technology is being tested in the following clinical trials:
Active Trials
Sept 26, 2011
EGEN, Inc. Collaborates With Nanotechnology Characterization Laboratory on Brain Cancer Therapy
Feb 2, 2011
FDA Awards EGEN, Inc. Orphan -Drug Grant for Clinical Development of EGEN-001 for Treatment of Ovarian Cancer
